meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - all population
6
mUC - L1 - PDL1 positive
2
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus SoC
durvalumab based treatment
durvalumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded